The 10 most-anticipated drug launches of 2020

FiercePharma with assistance from EvaluatePharma, have assembled a list of the top 10 most-anticipated new drug launches of 2020 based on estimated global sales in 2024. Eight out of the ten could break the blockbuster barrier in four short year putting a new batch of heavy hitters in pharma’s ranks.

First is AstraZeneca and Daiichi Sankyo’s breast cancer conjugate Enhertu (fam-trastuzumab deruxtecan-nxki), the only entry on in the list that has gained an FDA approval so far. The HER2-positive cancer therapy shrank tumors in 61% of patients in a phase 2 trial, putting its possible revenue at a chart-topping $2.4 billion in 2024, according to Evaluat and AZ’s betting up to $7 billion on that prospect.

Rounding out the top five are drugs from Bristol-Myers Squibb, Novartis, FibroGen and Immunomedicand.

Then there’s Novartis’ inclisiran, acquired in a much-discussed $9.7 billion pickup of The Medicines Company in December.

The 10 most-anticipated drug launches of 2020

  1. Enhertu
  2. Ozanimod
  3. Inclisiran
  4. Roxadustat
  5. Sacituzumab govitecan
  6. Filgotinib
  7. Palforzia (AR101)
  8. Valoctocogene roxaparvovec
  9. Rimegepant
  10. Risdiplam

Visit FiercePharma in the link before for more information on the background of these most anticipated drugs.

Source: FiercePharma